Evidence map›Paper›PMID 32847857›Full record

ArticleJournal of virology2020

Noncanonical Cell Death Induction by Reassortant Reovirus.

Roxana M Rodríguez Stewart, Vishnu Raghuram, Jameson T L Berry, Gaurav N Joshi, Bernardo A Mainou

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Roxana M Rodríguez StewartEmory University, Atlanta, Georgia, USA.
Vishnu RaghuramEmory University, Atlanta, Georgia, USA.
Jameson T L BerryEmory University, Atlanta, Georgia, USA.
Gaurav N JoshiEmory University, Atlanta, Georgia, USA.
Bernardo A MainouDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA bernardo.mainou@emory.edu.ORCID 0000-0002-7721-183X
Emory University · US

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Development of Oncolytic Reovirus for Triple-Negative Breast CancerR01AI146260 · NIAID · EMORY UNIVERSITY · PI LOWEN, ANICE C · 2020 to 2025
$1.9M
NCATS NIH HHS UL1 TR002378NCI NIH HHS P30 CA138292NIAID NIH HHS R01 AI146260
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) constitutes 10 to 15% of all breast cancer and is associated with worse prognosis than other subtypes of breast cancer. Current therapies are limited to cytotoxic chemotherapy, radiation, and surgery, leaving a need for targeted therapeutics to improve outcomes for TNBC patients. Mammalian orthoreovirus (reovirus) is a nonenveloped, segmented, double-stranded RNA virus in the

Indexed as

Antineoplastic AgentsApoptosisBreast NeoplasmsCaspase 3Cell DeathCell LineCell SurvivalHumansMitochondriaOncolytic VirotherapyOncolytic VirusesOrthoreovirus, MammalianReoviridaeViral ProteinsAntineoplastic AgentsCaspase 3Viral Proteinsanticancer therapycancercaspasescell deathcell signalingmitochondriaoncolytic virusesPARPreassortmentreovirus

Identifiers

PMID32847857
PMCPMC7592226
OpenAlexW3080661957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.